Quantcast

Latest JC virus Stories

2011-08-16 06:10:00

ATLANTA, Aug. 16, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML). This proof-of-concept trial will be conducted in multiple sclerosis (MS)...

2011-06-28 00:00:33

This report provides perspective on the MS landscape in light of Merck Serono's decision to discontinue development and marketing of cladribine for MS. Scottsdale, AZ (PRWEB) June 27, 2011 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Multiple Sclerosis," designed to provide critical strategic insight for pharma and biotech companies with a stake in the...

2011-02-23 10:17:00

Collaboration may lead to advances in detection of, treatment of, and even vaccination against colorectal and other cancers DALLAS and HOUSTON, Feb. 23, 2011 /PRNewswire-USNewswire/ -- Baylor Research Institute (BRI), the research arm of Baylor Health Care System, and bioinformatics pioneer Eureka Genomics (EG) have formed a strategic alliance to achieve a better understanding of the causes of colorectal cancer, potentially leading to advancements in the disease's prevention, management...

2010-11-09 12:08:00

AMSTERDAM, and RESEARCH TRIANGLE PARK, N.C., Nov. 9, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced that data supportive of the company's lead Phase 2 antiviral compound CMX001 were presented today during a late-breaker session by Hans H. Hirsch, MD, MSc, Professor of Clinical Virology, Division of Infectious Diseases, University of Basel, Switzerland, at the Antiviral Congress 2010 being held in Amsterdam, The...

2010-10-22 10:07:25

(Ivanhoe Newswire) -- The JC polyomavirus doesn't strike very often, but when it does, this mean bug can leave a devastating path. The JC polyomavirus is an opportunistic viral infection of the central nervous system. It usually preys on people with weakened immune systems, including people with AIDS, and almost always kills them. Researchers at Brown University, the University of Tubingen in Germany and Imperial College in London got together to study the precise structure and biology of how...

2010-10-20 20:04:56

The JC polyomavirus doesn't strike very often, but it's a mean bug that preys on people with weakened immune systems, including people with AIDS, and almost always kills them. Now an international team of scientists at Brown University, the University of Tbingen in Germany, and Imperial College in London has found a potential Achilles Heel and painted a target on it: The virus must bind to a very specific sugar molecule dangling from the side of the brain cells it attacks. Like the rebel...

2009-09-24 07:17:30

The Merkel cell polyomavirus (MCPyV) is the only human polyomavirus known to be associated with a rare skin cancer, known as Merkel cell carcinoma, according to a new study published online September 23 in the Journal of the National Cancer Institute. The majority of patients with Merkel cell carcinoma carry MCPyV, but little is known about the polyomavirus' prevalence in the general population and the association between circulating antibodies against MCPyV and the rare skin cancer. Denise...

2009-09-10 08:18:13

The source of PML, the JC virus, is found to be reactivated in multiple sclerosis patients receiving natalizumab treatment The virus responsible for PML (progressive multifocal leukoencephalopathy), a rare brain disease that typically affects AIDS patients and other individuals with compromised immune systems, has been found to be reactivated in multiple-sclerosis patients being treated with natalizumab (Tysabri). The findings, led by scientists at Beth Israel Deaconess Medical Center...

2009-04-09 07:39:23

The U.S. Food and Drug Administration says Genentech Inc. is withdrawing the psoriasis drug Raptiva and it will no longer be available in the United States. The FDA said the company is taking the action because of a potential risk of patients developing progressive multifocal leukoencephalopathy -- a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system. FDA officials said prescribers are being asked not to initiate new Raptiva (efalizumab)...

2009-02-19 10:35:37

The U.S. Food and Drug Administration issued a health advisory Thursday concerning serious events, including death, caused by the psoriasis drug Raptiva. The federal agency said it has received three confirmed, and one possible, reports of progressive multifocal leukoencephalopathy -- a rare brain infection -- in patients using Raptiva (efalizumab). Three of the patients have died. All four patients were treated with the drug for more than three years and none was receiving other treatments...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related